Nortriptyline Oral Solution Rx
Generic Name and Formulations:
Nortriptyline (as HCl) 10mg/5mL; contains alcohol 4%.
Various generic manufacturers
Indications for Nortriptyline Oral Solution:
Initially 25mg 3–4 times daily; max 150mg/day. Elderly and adolescents: 30–50mg/day in single or divided doses.
During or within 14 days of MAOIs. Concomitant linezolid or IV methylene blue. Acute post-MI.
Suicidality and antidepressant drugs.
Increased risk of suicidal thinking and behavior in children, adolescents and young adults; monitor for clinical worsening and unusual changes. Monitor for emergence of serotonin syndrome; discontinue if occurs. Mania/hypomania. Bipolar disorder. Psychosis. ECT. Cardiovascular disease. Angle-closure glaucoma. Urinary retention. Epilepsy. Hyperthyroidism. Diabetes. Liver disorders. Monitor plasma levels if dose >100mg/day. Elderly. Pregnancy. Nursing mothers.
See Contraindications. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Potentiates alcohol, sympathomimetics. CNS stimulation with reserpine. Potentiated by CYP2D6 inhibitors; monitor plasma levels with quinidine, cimetidine, SSRIs, phenothiazines, type 1C antiarrhythmics (eg, propafenone, flecainide). Antagonized by barbiturates, carbamazepine. Paralytic ileus, hyperpyrexia with anticholinergics. Blocks guanethidine.
Drowsiness, anticholinergic effects, CNS overstimulation, arrhythmias, extrapyramidal symptoms, hypo- or hypertension, nausea, fatigue, rash, headache, changes in blood sugar, photosensitivity, edema, blood dyscrasias, jaundice.
Caps—30; Soln—contact supplier
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Neuropathic Symptoms Worsen Quality of Life, Function in Hip, Knee Osteoarthritis
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- Switching From Buprenorphine-Naltrexone to XR-Naltrexone as Effective as XR-Naltrexone
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Human Diagnosis Project Aims to Address Challenges Among Uninsured
- Healthcare Technology Affects Younger Patient Satisfaction
- FDA Announces New Drug Shortages Task Force